{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:54Z","timestamp":1790913714434,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00277-020-04289-8","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T20:02:51Z","timestamp":1602014571000},"page":"85-96","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India"],"prefix":"10.1007","volume":"100","author":[{"given":"Abhijit","family":"Phukan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-3832","authenticated-orcid":false,"given":"Prakas Kumar","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuphan K.","family":"Dolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"4289_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"M H\u00f6glund","year":"2015","unstructured":"H\u00f6glund M, Sandin F, Simonsson B (2015) Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 94:241\u2013247. https:\/\/doi.org\/10.1007\/s00277-015-2314-2","journal-title":"Ann Hematol"},{"key":"4289_CR2","unstructured":"National Cancer Registry Programme (2016) Three year report of the population based cancer registries 2012\u201314. New Delhi: Indian Council of Medical Research; Bengaluru, India. https:\/\/ncdirindia.org\/NCRP\/ALL_NCRP_REPORTS\/PBCR_REPORT_2012_2014\/index.htm. Accessed March 2016"},{"key":"4289_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4103\/2278-330X.187593","volume":"5","author":"MK Singhal","year":"2016","unstructured":"Singhal MK, Sengar M, Nair R (2016) Summary of the published Indian data on chronic myeloid leukemia. South Asian J Cancer 5:162\u2013165. https:\/\/doi.org\/10.4103\/2278-330X.187593","journal-title":"South Asian J Cancer"},{"key":"4289_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/jnci\/25.1.85","volume":"25","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA (1960) Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25:85\u2013109. https:\/\/doi.org\/10.1093\/jnci\/25.1.85","journal-title":"J Natl Cancer Inst"},{"key":"4289_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2013293. https:\/\/doi.org\/10.1038\/243290a0","journal-title":"Nature"},{"key":"4289_CR6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079\u20131082. https:\/\/doi.org\/10.1126\/science.2408149","journal-title":"Science"},{"issue":"6","key":"4289_CR7","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1586\/14737140.8.6.853","volume":"8","author":"S Soverini","year":"2008","unstructured":"Soverini S, Martinelli G, Iacobucci I, Baccarani M (2008) Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev Anticancer Ther 8(6):853\u2013864. https:\/\/doi.org\/10.1586\/14737140.8.6.853","journal-title":"Expert Rev Anticancer Ther"},{"key":"4289_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561\u2013566. https:\/\/doi.org\/10.1038\/nm0596-561","journal-title":"Nat Med"},{"key":"4289_CR9","first-page":"1972","volume":"9","author":"JR Johnson","year":"2003","unstructured":"Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R (2003) Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 9:1972\u20131979","journal-title":"Clin Cancer Res"},{"key":"4289_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","volume":"38","author":"S Soverini","year":"2014","unstructured":"Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MWN, Martinelli G, M\u00fcller MC, Radich JP, Shah NP (2014) Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res 38:10\u201320. https:\/\/doi.org\/10.1016\/j.leukres.2013.09.011","journal-title":"Leuk Res"},{"key":"4289_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-3-642-54490-3_2","volume":"201","author":"M Lindauer","year":"2014","unstructured":"Lindauer M, Hochhaus A (2014) Dasatinib. Recent Results Cancer Res 201:27\u201365. https:\/\/doi.org\/10.1007\/978-3-642-54490-3_2","journal-title":"Recent Results Cancer Res"},{"key":"4289_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-3-642-54490-3_3","volume":"201","author":"BN Ostendorf","year":"2014","unstructured":"Ostendorf BN, le Coutre P, Kim TD, Quint\u00e1s-Cardama A (2014) Nilotinib. Recent Results Cancer Res 201:67\u201380. https:\/\/doi.org\/10.1007\/978-3-642-54490-3_3","journal-title":"Recent Results Cancer Res"},{"key":"4289_CR13","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","volume":"125","author":"J Wang","year":"2015","unstructured":"Wang J, Shen ZX, Saglio G, Jin J, He Huang YH, Xin D, Li J, Meng F, Zhu H, Hu J, Wang J, Hou M, Hertle S, Menssen HD, Ortmann CE, Tribouley C, Yuan Y, Baccarani M, Huang X (2015) Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood 125:2771\u20132778. https:\/\/doi.org\/10.1182\/blood-2014-09-601674","journal-title":"Blood"},{"key":"4289_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ejh.12423","volume":"94","author":"H Hjorth-Hansen","year":"2015","unstructured":"Hjorth-Hansen H, Stenke L, S\u00f6derlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, H\u00f6glund M, Lotfi K, Majeed W, Markev\u00e4rn B, Ohm L, Olsson-Str\u00f6mberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J (2015) Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomisedphase-2 study (NordCML006). Eur J Haematol 94:243\u2013250. https:\/\/doi.org\/10.1111\/ejh.12423","journal-title":"Eur J Haematol"},{"issue":"3","key":"4289_CR15","first-page":"S5","volume":"17","author":"MM Horowitz","year":"1996","unstructured":"Horowitz MM, Rowlings PA, Passweg JR (1996) Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 17(3):S5\u2013S6","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"4289_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1053\/j.seminhematol.2010.06.008","volume":"47","author":"J Radich","year":"2010","unstructured":"Radich J (2010) Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol 47(4):354\u2013361. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.008","journal-title":"Semin Hematol"},{"issue":"11","key":"4289_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457","journal-title":"N Engl J Med"},{"issue":"3","key":"4289_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686\u2013692. https:\/\/doi.org\/10.1182\/blood-2010-12-319038","journal-title":"Blood"},{"issue":"6","key":"4289_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, M\u00fcller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sau\u00dfele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884. https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"4289_CR20","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (2010) National Cancer Institute Updates CTCAE to v4.03. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (Accessed August 6, 2010)"},{"key":"4289_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/pds.1046","volume":"14","author":"S Tardieu","year":"2005","unstructured":"Tardieu S, Brun-Strang C, Berthaud P, Michallet M, Guilhot F, Rousselot P, Sambuc R (2005) Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf 14:545\u2013553. https:\/\/doi.org\/10.1002\/pds.1046","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4289_CR22","unstructured":"Cortes JE, Richard TS, Hagop K (2007) Chronic myelogenous leukemia. In: Padzur R, Coia LR, Hoskins WJ, Wagman LD (eds) Cancer management: a multidisciplinary approach, 10th edn. Lawrence: CMPMedica, p 789"},{"key":"4289_CR23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/s0140-6736(98)03030-x","volume":"352","author":"A Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352:1087\u20131092. https:\/\/doi.org\/10.1016\/s0140-6736(98)03030-x","journal-title":"Lancet"},{"issue":"3","key":"4289_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4103\/0971-5851.123719","volume":"34","author":"RR Prasad","year":"2013","unstructured":"Prasad RR, Singh P (2013) Report of chronic myeloid leukemia from Indira Gandhi Institute of Medical Sciences, Regional Cancer Center, 2002-2009. Indian J Med Paediatr Oncol 34(3):172\u2013174. https:\/\/doi.org\/10.4103\/0971-5851.123719","journal-title":"Indian J Med Paediatr Oncol"},{"key":"4289_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/0971-5851.123712","volume":"34","author":"P Mishra","year":"2013","unstructured":"Mishra P, Seth T, Mahapatra M, Saxena R (2013) Report of chronic myeloid leukemia in chronic phase from All India Institute of Medical Sciences, 1990-2010. Indian J Med Paediatr Oncol 34:159\u2013163. https:\/\/doi.org\/10.4103\/0971-5851.123712","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"1","key":"4289_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexmp.2006.03.004","volume":"81","author":"HF Mark","year":"2006","unstructured":"Mark HF, Sokolic RA, Mark Y (2006) Conventional cytogenetics and FISH in the detection of BCR\/ABL fusion in chronic myeloid leukemia (CML). Exp Mol Pathol 81(1):1\u20137. https:\/\/doi.org\/10.1016\/j.yexmp.2006.03.004","journal-title":"Exp Mol Pathol"},{"issue":"14","key":"4289_CR27","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031\u20131037. https:\/\/doi.org\/10.1056\/NEJM200104053441401","journal-title":"N Engl J Med"},{"issue":"9","key":"4289_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Carlo G-P, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346(9):645\u2013652. https:\/\/doi.org\/10.1056\/NEJMoa011573","journal-title":"N Engl J Med"},{"issue":"6","key":"4289_CR29","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","volume":"125","author":"DT Yeung","year":"2015","unstructured":"Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP (2015) TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 125(6):915\u2013923. https:\/\/doi.org\/10.1182\/blood-2014-07-590315","journal-title":"Blood"},{"issue":"14","key":"4289_CR30","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O'Brien S, Clark R, Goldman J, Marin D (2013) Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121(14):2739\u20132742. https:\/\/doi.org\/10.1182\/blood-2012-11-466037","journal-title":"Blood"},{"issue":"4","key":"4289_CR31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqu\u00e9 C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123(4):494\u2013500. https:\/\/doi.org\/10.1182\/blood-2013-06-511592","journal-title":"Blood"},{"issue":"12","key":"4289_CR32","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","volume":"110","author":"J Cortes","year":"2007","unstructured":"Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D (2007) Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110(12):4005\u20134011. https:\/\/doi.org\/10.1182\/blood-2007-03-080838","journal-title":"Blood"},{"issue":"6","key":"4289_CR33","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/ajh.23707","volume":"89","author":"DD Kim","year":"2014","unstructured":"Kim DD, Hamad N, Lee HG, Kamel-Reid S, Lipton JH (2014) BCR\/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am J Hematol 89(6):626\u2013632. https:\/\/doi.org\/10.1002\/ajh.23707","journal-title":"Am J Hematol"},{"issue":"6","key":"4289_CR34","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.v99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MWN, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99(6):1928\u20131937. https:\/\/doi.org\/10.1182\/blood.v99.6.1928","journal-title":"Blood"},{"issue":"19","key":"4289_CR35","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, M\u00fcller MC, Kaeda JS, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116(19):3758\u20133765. https:\/\/doi.org\/10.1182\/blood-2010-03-273979","journal-title":"Blood"},{"issue":"4","key":"4289_CR36","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","volume":"120","author":"S Luatti","year":"2012","unstructured":"Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, Specchia G, Zanatta L, Rege-Cambrin G, Mancini M, Abruzzese E, Zaccaria A, Grimoldi MG, Gozzetti A, Ameli G, Capucci MA, Palka G, Bernasconi P, Palandri F, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M, Testoni N, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML (2012) Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 120(4):761\u2013767. https:\/\/doi.org\/10.1182\/blood-2011-10-384651","journal-title":"Blood"},{"key":"4289_CR37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3332\/ecancer.2016.679","volume":"10","author":"LC Kuntegowdanahalli","year":"2016","unstructured":"Kuntegowdanahalli LC, Kanakasetty GB, Thanky AH, Dasappa L, Jacob LA, Mallekavu SB, Lakkavalli RK, Kadabur LN, Haleshappa RA (2016) Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era\u2014experience from tertiary oncology centre in southern India. Ecancer 10:679. https:\/\/doi.org\/10.3332\/ecancer.2016.679","journal-title":"Ecancer"},{"issue":"7","key":"4289_CR38","doi-asserted-by":"publisher","first-page":"7187","DOI":"10.1007\/s13277-014-1926-9","volume":"35","author":"S Kagita","year":"2014","unstructured":"Kagita S, Uppalapati S, Jiwatani S, Linga VG, Gundeti S, Nagesh N, Digumarti R (2014) Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India. Tumour Biol 35(7):7187\u20137193. https:\/\/doi.org\/10.1007\/s13277-014-1926-9","journal-title":"Tumour Biol"},{"issue":"2","key":"4289_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12288-011-0108-9","volume":"28","author":"A Mukhopadhyay","year":"2012","unstructured":"Mukhopadhyay A, Dasgupta S, Mukhopadhyay S, Bose CK, Sarkar S, Gharami F, Koner S, Basak J, Roy UK (2012) Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: an experience from eastern India. Indian J Hematol Blood Transfus 28(2):82\u201388. https:\/\/doi.org\/10.1007\/s12288-011-0108-9","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"3","key":"4289_CR40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4103\/0971-5851.123736","volume":"34","author":"G Babu","year":"2013","unstructured":"Babu G (2013) Report of patients with chronic myeloid leukemia Kidwai Memorial Institute of Oncology, Bangalore over 15 years. Indian J Med Paediatr Oncol 34(3):196\u2013198. https:\/\/doi.org\/10.4103\/0971-5851.123736","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"5","key":"4289_CR41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3816\/CLML.2010.n.065","volume":"10","author":"R Salie","year":"2010","unstructured":"Salie R, Silver RT (2010) Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 10(5):331\u2013335. https:\/\/doi.org\/10.3816\/CLML.2010.n.065","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4289_CR42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2147\/BTT.S5775","volume":"4","author":"TI Mughal","year":"2010","unstructured":"Mughal TI, Schrieber A (2010) Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics 4:315\u2013323. https:\/\/doi.org\/10.2147\/BTT.S5775","journal-title":"Biologics"},{"issue":"3","key":"4289_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/0971-5851.123721","volume":"34","author":"SS Ray","year":"2013","unstructured":"Ray SS, Chakraborty P, Chaudhuri U, Ganesh (2013) Report of chronic myeloid leukemia in chronic phase from eastern India, Institute of Hematology and Transfusion Medicine, Kolkata, 2001-2009. Indian J Med Paediatr Oncol 34(3):175\u2013176. https:\/\/doi.org\/10.4103\/0971-5851.123721","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"12","key":"4289_CR44","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.clml.2017.07.255","volume":"17","author":"AE Eskazan","year":"2017","unstructured":"Eskazan AE, Sadri S, Keskin D, Ayer M, Kantarcioglu B, Demirel N, Aydin D, AydinliF YO, Ozunal IE, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T (2017) Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and Glivec. Clin Lymphoma Myeloma Leuk 17(12):804\u2013811. https:\/\/doi.org\/10.1016\/j.clml.2017.07.255","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"4289_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.31768\/2312-8852.2017.39(2):151-154","volume":"39","author":"S Lejniece","year":"2017","unstructured":"Lejniece S, Udre I, Rivkina A (2017) Generic imatinib in the treatment of chronic myeloid leukemia: two years\u2019 experience in Latvia. Exp Oncol 39(2):151\u2013154","journal-title":"Exp Oncol"},{"issue":"7","key":"4289_CR46","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.clml.2017.05.006","volume":"17","author":"M Danthala","year":"2017","unstructured":"Danthala M, Gundeti S, Kuruva SP, Puligundla KC, Adusumilli P, PillaiKarnam A, Bala S, Konatam ML, Maddali LS, Digumarti RR (2017) Generic imatinib in chronic myeloid leukemia: survival of the cheapest. Clin Lymphoma Myeloma Leuk 17(7):457\u2013462. https:\/\/doi.org\/10.1016\/j.clml.2017.05.006","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4289_CR47","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1182\/blood-2019-126495","volume":"134","author":"SS Bhatwadekar","year":"2019","unstructured":"Bhatwadekar SS, Deshpande SV, Mehta A, Shah P (2019) Efficacy and safety of generic imatinib compared to Glivec in chronic phase - chronic myeloid leukemia-single center retrospective analysis. Blood 134:4162. https:\/\/doi.org\/10.1182\/blood-2019-126495","journal-title":"Blood"},{"key":"4289_CR48","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.26452\/ijrps.v10i4.1604","volume":"10","author":"S Samrat","year":"2019","unstructured":"Samrat S, Meena LP, Chakravarty J, Rai M (2019) Treatment of chronic myeloid leukemia with generic imatinib in patients from northeastern part of India. Int J Res Pharm Sci 10:3107\u20133113. https:\/\/doi.org\/10.26452\/ijrps.v10i4.1604","journal-title":"Int J Res Pharm Sci"},{"key":"4289_CR49","doi-asserted-by":"publisher","first-page":"6559","DOI":"10.1002\/cam4.2545","volume":"8","author":"I Abou Dalle","year":"2019","unstructured":"Abou Dalle I, Kantarjian H, Burger J, Estrov Z, Ohanian M, Verstovsek S, Ravandi F, Borthakur G, Garcia-Manero G, Jabbour E (2019) Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med 8:6559\u20136565. https:\/\/doi.org\/10.1002\/cam4.2545","journal-title":"Cancer Med"},{"key":"4289_CR50","unstructured":"Supreme Court rules for cheap cancer drug. Updated: Apr 2, 2013, 05:42 IST. Read more at: https:\/\/timesofindia.indiatimes.com\/business\/india-business\/Supreme-Court-rules-for-cheap-cancer-drug\/articleshow\/19331267.cms. Accessed 2 April 2013"},{"key":"4289_CR51","unstructured":"Glivec from Novartis India. https:\/\/dir.indiamart.com\/impcat\/glivec-tablets.html"},{"key":"4289_CR52","unstructured":"Imatinib Price of 22 Brands in India. https:\/\/www.medindia.net\/drug-price\/imatinib.htm. Accessed 2 February 2017"},{"key":"4289_CR53","unstructured":"Imatinib brands in India. http:\/\/www.drugsupdate.com\/brand\/showavailablebrands\/65"},{"key":"4289_CR54","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.htct.2018.10.003","volume":"41","author":"TP de Almeida Filho","year":"2019","unstructured":"de Almeida Filho TP, Maia Filho PA, Barbosa MC, Dutra LLA, Castro MFD, Duarte FB et al (2019) Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase? Hematol Transfus Cell Ther 41:114\u2013118. https:\/\/doi.org\/10.1016\/j.htct.2018.10.003","journal-title":"Hematol Transfus Cell Ther"},{"key":"4289_CR55","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A et al (2019) The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia 33:1173\u20131183. https:\/\/doi.org\/10.1038\/s41375-018-0341-4","journal-title":"Leukemia"},{"key":"4289_CR56","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2353\/jmoldx.2009.090008","volume":"11","author":"N Jinawath","year":"2009","unstructured":"Jinawath N, Norris-Kirby A, Smith BD, Gocke CD, Batista DA, Griffin CA, Murphy KM (2009) A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia. J Mol Diagn 11:359\u2013363. https:\/\/doi.org\/10.2353\/jmoldx.2009.090008","journal-title":"J Mol Diagn"},{"issue":"15","key":"4289_CR57","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen I, Goldman JM, Radich JP, International Randomised Study of Interferon versus STI571 (IRIS) Study Group (2003) Frequency of major molecular responses to imatinib or interferon-alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349(15):1423\u20131432","journal-title":"N Engl J Med"},{"issue":"1","key":"4289_CR58","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"TP Hughes","year":"2006","unstructured":"Hughes TP, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1):28\u201337","journal-title":"Blood"},{"issue":"8","key":"4289_CR59","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW et al (2008) Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112(8):3330\u20133338. https:\/\/doi.org\/10.1182\/blood-2008-04-150680","journal-title":"Blood"},{"issue":"10","key":"4289_CR60","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, M\u00fcller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172\u20132175. https:\/\/doi.org\/10.1038\/leu.2012.104","journal-title":"Leukemia"},{"issue":"1","key":"4289_CR61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/10428194.2016.1190974","volume":"58","author":"R Arora","year":"2017","unstructured":"Arora R, Press RD (2017) Measurement of BCR-ABL1 transcripts on the international scale in the United States: current status and best practices. Leuk Lymphoma 58(1):8\u201316. https:\/\/doi.org\/10.1080\/10428194.2016.1190974","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04289-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04289-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04289-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T05:55:52Z","timestamp":1633499752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04289-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4289"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04289-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"6 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed written consent was taken from individual patient or their legal guardians prior to their inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}